Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population‐based study in France

The excess mortality observed in Acute Myeloblastic Leukaemia (AML) patients, partly attributed to unequal access to curative treatments, could be linked to care pathways.

[1]  R. Walter,et al.  Practice patterns and outcomes for adults with acute myeloid leukemia receiving care in community vs academic settings. , 2020, Hematology. American Society of Hematology. Education Program.

[2]  M. Othus,et al.  Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Niederwieser,et al.  Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. , 2020, Blood advances.

[4]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[5]  C. Delpierre,et al.  Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients , 2019, BMC Cancer.

[6]  S. Paolini,et al.  Acute Myeloid Leukemia Mutations: Therapeutic Implications , 2019, International journal of molecular sciences.

[7]  M. Jongen‐Lavrencic,et al.  Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. , 2018, Cancer epidemiology.

[8]  E. Estey.  Acute myeloid leukemia: 2019 update on risk‐stratification and management , 2018, American journal of hematology.

[9]  T. Gray,et al.  Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia , 2017, Current Geriatrics Reports.

[10]  V. Bouvier,et al.  No effect of comorbidities on the association between social deprivation and geographical access to the reference care center in the management of colon cancer. , 2017, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[11]  F. Appelbaum,et al.  Early mortality and overall survival of acute myeloid leukemia based on facility type , 2017, American journal of hematology.

[12]  M. Nørgaard,et al.  Improved outcome in acute myeloid leukemia patients enrolled in clinical trials: A national population-based cohort study of Danish intensive chemotherapy patients , 2016, Oncotarget.

[13]  I. de Kouchkovsky,et al.  ‘Acute myeloid leukemia: a comprehensive review and 2016 update' , 2016, Blood Cancer Journal.

[14]  N. Magné,et al.  Social inequalities and cancer: can the European deprivation index predict patients' difficulties in health care access? a pilot study , 2015, Oncotarget.

[15]  S. Mineishi,et al.  Nonbiological factors affecting survival in younger patients with acute myeloid leukemia , 2015, Cancer.

[16]  V. Bhatt,et al.  Impact of hospital volume on outcomes of patients undergoing chemotherapy for acute myeloid leukemia: a matched cohort study. , 2015, Blood.

[17]  Ken H. Young,et al.  Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. , 2015, Leukemia research.

[18]  P. Vyas,et al.  Reprint of: Allogeneic hematopoietic cell transplantation for acute myeloid leukemia. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[20]  D. Weisdorf,et al.  Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.

[21]  Cyrille Delpierre,et al.  Construction of an adaptable European transnational ecological deprivation index: the French version , 2012, Journal of Epidemiology & Community Health.

[22]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[23]  G. Juliusson.  Older patients with acute myeloid leukemia benefit from intensive chemotherapy: an update from the Swedish Acute Leukemia Registry. , 2011, Clinical Lymphoma, Myeloma & Leukemia.

[24]  K. Bendix,et al.  Reasons for treating secondary AML as de novo AML , 2010, European journal of haematology.

[25]  J. Karp,et al.  New agents in acute myeloid leukemia: Beyond cytarabine and anthracyclines , 2009, Current oncology reports.

[26]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[27]  P. Dickman,et al.  Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in sweden. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Jiong Hu,et al.  Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia , 2009, Proceedings of the National Academy of Sciences.

[29]  M Colonna,et al.  Cancer incidence and mortality in France over the period 1980-2005. , 2008, Revue d'epidemiologie et de sante publique.

[30]  R. Larson.  Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? , 2007, Best practice & research. Clinical haematology.

[31]  L. Degos.  Traitement de la leucémie aiguë promyélocytaire par acide tout trans-rétinoïque , 1995 .

[32]  E. Estey,et al.  CME Information: Acute myeloid leukemia: 2014 update on risk-stratification and management , 2014 .

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.